TherapeuticsMD (TXMD) Net Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
TherapeuticsMD (TXMD) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 38.95% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -49.89% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 33.59% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 38.53% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -51.84% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -11.43% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 1.06% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 106.37% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 30.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.64% |
| Mar 31, 2026 | 28.23% |
| Dec 31, 2025 | 26.09% |
| Sep 30, 2025 | -62.84% |
| Jun 30, 2025 | 26.05% |
| Mar 31, 2025 | 26.62% |
| Dec 31, 2024 | -92.92% |
| Sep 30, 2024 | 77.91% |
| Jun 30, 2024 | 27.15% |
| Mar 31, 2024 | -26.08% |
| Dec 31, 2023 | -76.22% |
| Sep 30, 2023 | 43.93% |
| Jun 30, 2023 | 60.79% |
| Mar 31, 2023 | -43.24% |
| Dec 31, 2022 | -156.47% |
| Sep 30, 2022 | 39.37% |
| Jun 30, 2022 | -63.22% |
| Mar 31, 2022 | 15.84% |
| Dec 31, 2021 | 54.46% |
| Sep 30, 2021 | -29.76% |